Glomerular filtration rate slopes have significantly improved among renal transplants in the United States

Transplantation

Volumn 90, Issue 12, 2010, Pages 1499-1505

  Srinivas, Titte R ^a   Flechner, Stuart M ^a   Poggio, Emilio D ^a   Askar, Medhat ^a   Goldfarb, David A ^a   Navaneethan, Sankar D ^a   Schold, Jesse D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

GFR intercept; GFR slope; Immunosuppression; Outcomes; Renal function

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANEL REACTIVE ANTIBODY; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BODY MASS; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEALTH INSURANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REGISTER; RENAL REPLACEMENT THERAPY; RETRANSPLANTATION; SURVIVAL RATE; UNITED STATES;

ADOLESCENT; ADULT; AGED; CONTINENTAL POPULATION GROUPS; DIABETIC NEPHROPATHIES; DIET; ETHNIC GROUPS; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; REGISTRIES; REOPERATION; TISSUE DONORS; TREATMENT OUTCOME; UNITED STATES;

EID: 78650849203     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182003dda     Document Type: Article

References (43)

1. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6(5 pt 2): 1111.
2. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, doubleblind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564.
3. Luan FL, Steffick DE, Gadegbeku C, et al. Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant 2009; 9: 160.
4. Schold JD, Santos A, Rehman S, et al. The success of continued steroid avoidance after kidney transplantation in the US. Am J Transplant 2009; 9: 2768.
5. Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: Objectives and interim result. Clin J Am Soc Nephrol 2008; 3(suppl 2): S101.
6. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
7. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation.NEngl J Med 2007; 357: 2562.
8. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883.
9. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070.
10. Merion RM, Ashby VB, Wolfe RA, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 2005; 294: 2726.
11. Metzger RA, Delmonico FL, Feng S, et al. Expanded criteria donors for kidney transplantation. Am J Transplant 2003; 3(suppl 4): 114.
12. Marks WH, Wagner D, Pearson TC, et al. Organ donation and utilization, 1995-2004: Entering the collaborative era. Am J Transplant 2006; 6(5 pt 2): 1101.
13. Reese PP, Feldman HI, McBride MA, et al. Substantial variation in the acceptance of medically complex live kidney donors across US renal transplant centers. Am J Transplant 2008; 8: 2062.
14. Textor SC, Taler SJ, Driscoll N, et al. Blood pressure and renal function after kidney donation from hypertensive living donors. Transplantation 2004; 78: 276.
15. Textor S, Taler S. Expanding criteria for living kidney donors: What are the limits? Transplant Rev (Orlando) 2008; 22: 187.
16. Heimbach JK, Taler SJ, Prieto M, et al. Obesity in living kidney donors: Clinical characteristics and outcomes in the era of laparoscopic donor nephrectomy. Am J Transplant 2005; 5: 1057.
17. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
18. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908.
19. Hunsicker LG, Bennett LE. Acute rejection reduces creatinine clearance (Ccr) at 6 months following renal transplantation but does not affect subsequent slope of Ccr [abstract]. Transplantation 1999; 67: S83.
20. Gourishankar S, Hunsicker LG, Jhangri GS, et al. The stability of the glomerular filtration rate after renal transplantation is improving. J Am Soc Nephrol 2003; 14: 2387.
21. Kasiske BL, Gaston RS, Gourishankar S, et al. Long-term deterioration of kidney allograft function. Am J Transplant 2005; 5: 1405.
22. Marcén R, Morales JM, Fernández-Rodriguez A, et al. Long-term graft function changes in kidney transplant recipients. NDT Plus 2010; 3(suppl 2): ii2.
23. Mariat C, Alamartine E, Barthelemy JC, et al. Assessing renal graft function in clinical trials: Can tests predicting glomerular filtration rate substitute for a reference method? Kidney Int 2004; 65: 289.
24. Limaye S, O'Kelly P, Harmon G, et al. Improved graft survival in highly sensitized patients undergoing renal transplantation after the introduction of a clinically validated flow cytometry crossmatch. Transplantation 2009; 87: 1052.
25. Lindemann M, Nyadu B, Heinemann FM, et al. High negative predictive value of an amplified flow cytometry crossmatch before living donor kidney transplantation. Hum Immunol 2010; 71: 771.
26. Graff RJ, Xiao H, Schnitzler MA, et al. The role of positive flow cytometry crossmatch in late renal allograft loss. Hum Immunol 2009; 70: 502.
27. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.
28. Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: New insights into mechanisms and treatment. Curr Opin Organ Transplant 2010; 15: 8.
29. Humar A, Snydman D; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9(suppl 4): S78.
30. Schold JD, Rehman S, Kayle LK, et al. Treatment for BK virus: Incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 2009; 22: 626.
31. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5: 582.
32. Schold JD, Kaplan B, Howard RJ, et al. Are we frozen in time? Analysis of the utilization and efficacy of pulsatile perfusion in renal transplantation. Am J Transplant 2005; 5: 1681.
33. Moers C, Smits JM, Maathuis MH, et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 2009; 360: 7.
34. Meier-Kriesche HU, Ojo AO, Hanson JA, et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000; 70: 1098.
35. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604.
36. Kaplan B, Schold J, Meier-Kriesche HU. Overview of large database analysis in renal transplantation. Am J Transplant 2003; 3: 1052.
37. Meyers CM, Kirk AD. Workshop on late renal allograft dysfunction. Am J Transplant 2005; 5: 1600.
38. Serur D, Saal S, Wang J, et al. Deceased-donor kidney transplantation: Improvement in long-term survival. Nephrol Dial Transplant 2010; Epub.
39. Hariharan S, McBride MA, Cohen EP. Evolution of endpoints for renal transplant outcome. Am J Transplant 2003; 3: 933.
40. Kaplan B, Schold J, Meier-Kriesche HU. Poor predictive value of serum creatinine for renal allograft loss. Am J Transplant 2003; 3: 1560.
41. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
42. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.
43. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function- Measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473.